{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:59:39Z","timestamp":1790816379747,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.pharmthera.2015.08.003","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T02:00:41Z","timestamp":1439949641000},"page":"36-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Inherited cardiomyopathies\u2014Novel therapies"],"prefix":"10.1016","volume":"155","author":[{"given":"Dror B.","family":"Leviner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Hochhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.08.003_bb0005","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0010","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.amjcard.2006.07.029","article-title":"Determinants for clinical diagnosis of hypertrophic cardiomyopathy","volume":"98","author":"Adabag","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0015","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/01.CIR.101.21.2490","article-title":"Clinical profile and outcome of idiopathic restrictive cardiomyopathy","volume":"101","author":"Ammash","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0020","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa033349","article-title":"Glycogen storage diseases presenting as hypertrophic cardiomyopathy","volume":"352","author":"Arad","year":"2005","journal-title":"N Engl J Med"},{"issue":"389","key":"10.1016\/j.pharmthera.2015.08.003_bb0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol Med"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: The INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diab Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0035","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1161\/CIRCEP.111.963066","article-title":"Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia\/cardiomyopathy: Arrhythmia-free survival after endo-epicardial substrate based mapping and ablation","volume":"4","author":"Bai","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/scrt117","article-title":"The Aastrom experience","volume":"3","author":"Bartel","year":"2012","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0045","first-page":"3893","article-title":"Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice","volume":"118","author":"Baudenbacher","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0050","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0055","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1172\/JCI70877","article-title":"Enhanced autophagy ameliorates cardiac proteinopathy","volume":"123","author":"Bhuiyan","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0065","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nm0897-855","article-title":"Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene","volume":"3","author":"Botto","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1074248413508003","article-title":"Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia","volume":"19","author":"Brown","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0075","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jacc.2004.11.066","article-title":"Clinical and genetic issues in familial dilated cardiomyopathy","volume":"45","author":"Burkett","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.106.641472","article-title":"Prospective familial assessment in dilated cardiomyopathy: Cardiac autoantibodies predict disease development in asymptomatic relatives","volume":"115","author":"Caforio","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: Studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Castano","year":"2012","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0095","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJMra1205406","article-title":"Autophagy in human health and disease","volume":"368","author":"Choi","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0100","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1161\/CIRCULATIONAHA.107.743120","article-title":"Results of the Predictors of Response to CRT (PROSPECT) trial","volume":"117","author":"Chung","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0105","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1038\/mtna.2014.57","article-title":"Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease","volume":"3","author":"Clayton","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","article-title":"The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial","volume":"378","author":"Cleland","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0115","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0120","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0125","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0130","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1161\/01.RES.0000126923.46786.FD","article-title":"Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations","volume":"94","author":"Coutu","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0135","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2015.01.045","article-title":"Exercise triggers ARVC phenotype in mice expressing a disease-causing mutated version of human plakophilin-2","volume":"65","author":"Cruz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/HCO.0b013e328337ba52","article-title":"The genetics of dilated cardiomyopathy","volume":"25","author":"Dellefave","year":"2010","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/ng.309","article-title":"A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia","volume":"41","author":"Dhandapany","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0155","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jacc.2011.01.072","article-title":"Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects","volume":"58","author":"Diegoli","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0160","doi-asserted-by":"crossref","first-page":"C1148","DOI":"10.1152\/ajpcell.00551.2006","article-title":"Blebbistatin specifically inhibits actin\u2013myosin interaction in mouse cardiac muscle","volume":"293","author":"Dou","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0140","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","article-title":"Danon disease: Clinical features, evaluation, and management","volume":"7","author":"D'Souza","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0165","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jacc.2004.09.078","article-title":"Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy","volume":"45","author":"Duboc","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/cvr\/cvn310","article-title":"Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction","volume":"81","author":"Duda","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0175","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1634\/stemcells.2006-0374","article-title":"Cellular cardiomyoplasty: Improvement of left ventricular function correlates with the release of cardioactive cytokines","volume":"25","author":"Ebelt","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/HJH.0b013e3283658a53","article-title":"Mitochondrial targeted peptides attenuate residual myocardial damage after reversal of experimental renovascular hypertension","volume":"32","author":"Eirin","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0190","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0185","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0195","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pbiomolbio.2012.08.010","article-title":"Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial","volume":"110","author":"Fabritz","year":"2012","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0200","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jacc.2010.09.046","article-title":"Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice","volume":"57","author":"Fabritz","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10741-009-9156-8","article-title":"Cardiomyopathy in Duchenne muscular dystrophy: Pathogenesis and therapeutics","volume":"15","author":"Fayssoil","year":"2010","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0210","doi-asserted-by":"crossref","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy","volume":"8","author":"Finkel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0215","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.yjmcc.2011.07.026","article-title":"Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein","volume":"51","author":"Gaffin","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0220","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2353\/ajpath.2010.090468","article-title":"Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies","volume":"176","author":"Gazzerro","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0225","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","article-title":"Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis","volume":"148","author":"Gillmore","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0230","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1161\/CIRCRESAHA.113.302593","article-title":"Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation","volume":"113","author":"Gonzalez-Quesada","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0235","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.pharmthera.2007.06.014","article-title":"Small molecules affecting transcription in Friedreich ataxia","volume":"116","author":"Gottesfeld","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0240","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1152\/physrev.00027.2011","article-title":"The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology","volume":"92","author":"Guerriero","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0245","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa1110186","article-title":"Truncations of titin causing dilated cardiomyopathy","volume":"366","author":"Herman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0250","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","article-title":"Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: A pilot randomized trial to modify disease expression","volume":"3","author":"Ho","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0255","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0195-668X(02)00387-1","article-title":"Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings","volume":"24","author":"Holmgren","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0260","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0735-1097(00)01109-8","article-title":"Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy","volume":"37","author":"Iwata","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0265","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI200420149","article-title":"Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy","volume":"113","author":"Jahns","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0270","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1055\/s-0030-1251506","article-title":"Targeting receptor antibodies in immune cardiomyopathy","volume":"36","author":"Jahns","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0275","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2013.06.033","article-title":"Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia\/cardiomyopathy-associated desmosomal mutation carriers","volume":"62","author":"James","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0280","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0285","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.4049\/jimmunol.1303326","article-title":"Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa","volume":"193","author":"Joly","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0290","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.jacc.2010.12.036","article-title":"Distinguishing arrhythmogenic right ventricular cardiomyopathy\/dysplasia-associated mutations from background genetic noise","volume":"57","author":"Kapplinger","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0295","doi-asserted-by":"crossref","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0300","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: Major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0305","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","article-title":"Characterization of a chemically modified plant cell culture expressed human alpha-galactosidase-A enzyme for treatment of Fabry disease","volume":"114","author":"Kizhner","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: Beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0315","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/hum.2012.234","article-title":"Clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy","volume":"24","author":"Koo","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI78652","article-title":"Autophagy: A druggable process that is deregulated in aging and human disease","volume":"125","author":"Kroemer","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0325","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2007.02.061","article-title":"Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype","volume":"49","author":"Kubo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0330","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jcin.2008.05.009","article-title":"Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation","volume":"1","author":"Kwon","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0335","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/CIRCULATIONAHA.110.954446","article-title":"Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy","volume":"122","author":"Landstrom","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0340","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/scrt345","article-title":"Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages","volume":"4","author":"Ledford","year":"2013","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0345","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1475-2840-11-73","article-title":"Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid","volume":"11","author":"Li","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0350","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jacc.2013.05.035","article-title":"A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure","volume":"62","author":"Li","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0355","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4161\/auto.19469","article-title":"Autophagy in lysosomal storage disorders","volume":"8","author":"Lieberman","year":"2012","journal-title":"Autophagy"},{"issue":"389","key":"10.1016\/j.pharmthera.2015.08.003_bb0360","first-page":"389","article-title":"CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia","volume":"21","author":"Lin","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0365","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.108.790501","article-title":"Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms","volume":"119","author":"Lombardi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0370","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mt.2014.224","article-title":"Enzyme enhancers for the treatment of Fabry and Pompe disease","volume":"23","author":"Lukas","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0375","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: A potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0380","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/eurheartj\/ehq025","article-title":"Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: Proposed modification of the Task Force Criteria","volume":"31","author":"Marcus","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0395","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCHEARTFAILURE.109.922872","article-title":"Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy","volume":"3","author":"Maron","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0385","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0390","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacc.2008.11.069","volume":"54","author":"Maron","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0400","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0405","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/eurheartj\/ehq136","article-title":"Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy","volume":"31","author":"Melacini","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0410","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1399-0004.2008.01062.x","article-title":"Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology","volume":"74","author":"Menon","year":"2008","journal-title":"Clin Genet"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0415","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCHEARTFAILURE.112.968941","article-title":"In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice","volume":"5","author":"Merkulov","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0420","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0425","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/euhj.1998.1145","article-title":"Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy","volume":"20","author":"Mestroni","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0430","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1093\/hmg\/dds265","article-title":"Abnormal p38alpha mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A\/C gene mutation","volume":"21","author":"Muchir","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0435","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/eurjhf\/hfs118","article-title":"Administration of the cyclic peptide COR-1 in humans (phase I study): Ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters","volume":"14","author":"Munch","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0440","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jacc.2010.11.017","article-title":"Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy","volume":"57","author":"Nodari","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2015.08.003_bb0445","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0450","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0455","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijcard.2013.11.037","article-title":"Titin mutation in familial restrictive cardiomyopathy","volume":"171","author":"Peled","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0460","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.yjmcc.2010.09.010","article-title":"Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy","volume":"49","author":"Pena","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0465","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","article-title":"The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: A pilot, randomized study","volume":"11","author":"Penicka","year":"2009","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0470","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijcard.2003.10.037","article-title":"Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital","volume":"97","author":"Peters","year":"2004","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0475","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1161\/CIRCULATIONAHA.110.976936","article-title":"Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: Impact of genetics and revised task force criteria","volume":"123","author":"Quarta","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0480","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","article-title":"Diagnostic work-up in cardiomyopathies: Bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0485","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","article-title":"Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy","volume":"107","author":"Richard","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0490","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCULATIONAHA.104.507723","article-title":"Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy","volume":"112","author":"Rickers","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0495","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00441-012-1402-z","article-title":"The changing spectrum of arrhythmogenic (right ventricular) cardiomyopathy","volume":"348","author":"Rizzo","year":"2012","journal-title":"Cell Tissue Res"},{"issue":"222\u2013228","key":"10.1016\/j.pharmthera.2015.08.003_bb0500","first-page":"e221","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0505","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ejhf.181","article-title":"Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members","volume":"16","author":"Saberniak","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0510","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1542\/peds.2004-0718","article-title":"Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease","volume":"114","author":"Scaglia","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0515","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yjmcc.2013.12.016","article-title":"Ubiquitin-proteasome system and hereditary cardiomyopathies","volume":"71","author":"Schlossarek","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0520","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1172\/JCI200214677","article-title":"The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model","volume":"109","author":"Semsarian","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0530","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCHEARTFAILURE.109.930321","article-title":"Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure","volume":"3","author":"Shen","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0525","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1093\/hmg\/ddv070","article-title":"Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice","volume":"24","author":"Shen","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0535","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jacc.2004.04.055","article-title":"Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy","volume":"44","author":"Staudt","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0540","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/HCO.0b013e32835fb728","article-title":"Genetic testing in cardiovascular medicine: Current landscape and future horizons","volume":"28","author":"Sturm","year":"2013","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0545","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cellsig.2012.09.025","article-title":"Beyond cell adhesion: The role of armadillo proteins in the heart","volume":"25","author":"Swope","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0550","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1161\/01.CIR.0000108396.65446.21","article-title":"Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and\/or dysplasia","volume":"108","author":"Tabib","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0555","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0560","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.CIR.0000121426.43044.2B","article-title":"Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy","volume":"109","author":"Tsybouleva","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0565","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1172\/JCI73937","article-title":"Pharmacologic agents targeting autophagy","volume":"125","author":"Vakifahmetoglu-Norberg","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0570","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0575","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","article-title":"Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: Evidence supporting the concept of arrhythmogenic cardiomyopathy","volume":"14","author":"van der Zwaag","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0580","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jacc.2011.08.078","article-title":"Risk factors for malignant ventricular arrhythmias in lamin a\/c mutation carriers a European cohort study","volume":"59","author":"van Rijsingen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0585","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCGENETICS.113.000374","article-title":"Outcome in phospholamban R14del carriers: Results of a large multicentre cohort study","volume":"7","author":"van Rijsingen","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0590","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2009-11-252874","article-title":"Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype","volume":"115","author":"van Til","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0595","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.112.276519","article-title":"Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up","volume":"112","author":"Vrtovec","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0600","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cardfail.2010.11.007","article-title":"Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy","volume":"17","author":"Vrtovec","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0605","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: Evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0610","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0615","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cellimm.2009.09.001","article-title":"Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction","volume":"260","author":"Xiao","year":"2009","journal-title":"Cell Immunol"},{"issue":"7","key":"10.1016\/j.pharmthera.2015.08.003_bb0620","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/mt.2015.87","article-title":"Coformulation of a novel human alpha-galactosidase a with the pharmacological chaperone AT1001 leads to improved substrate reduction in Fabry mice","volume":"23","author":"Xu","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0625","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1536\/ihj.48.715","article-title":"A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker","volume":"48","author":"Yamazaki","year":"2007","journal-title":"Int Heart J"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0630","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0635","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.hlc.2011.06.004","article-title":"A randomised, placebo-controlled trial of carvedilol in early familial dilated cardiomyopathy","volume":"20","author":"Yeoh","year":"2011","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0640","doi-asserted-by":"crossref","first-page":"e57631","DOI":"10.1371\/journal.pone.0057631","article-title":"Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients","volume":"8","author":"Young-Gqamana","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.08.003_bb0645","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","article-title":"Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: Analysis of recurrent cardiovascular events and mortality","volume":"114","author":"Zsebo","year":"2014","journal-title":"Circ Res"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T16:25:44Z","timestamp":1653063944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725815001618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":129,"alternative-id":["S0163725815001618"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.08.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inherited cardiomyopathies\u2014Novel therapies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}